Embecta (EMBC) DIvidends Date & History

Key Takeaways

• Embecta Corp. (EMBC) offers a trailing dividend yield of approximately 6.5%, significantly above the medical devices industry average of around 1-2%.
• The company maintained a stable quarterly dividend of $0.15 per share from late 2022 through early 2026, resulting in an annual payout of $0.60.
• On May 5, 2026, EMBC announced a sharp reduction to $0.01 quarterly, payable June 15, 2026 (record date May 28), to prioritize debt reduction and a new $100 million share repurchase program.
• Payout ratio of 25.4% indicates strong historical coverage by earnings, with TTM levered free cash flow of $189 million supporting payments.
• High debt of $1.41 billion raises sustainability questions post-cut, though ongoing debt paydown enhances long-term stability.
• Attractive for yield-seeking investors comfortable with recent policy shift amid U.S. market challenges.

Dividend Overview

Embecta Corp. (EMBC), a global medical device company specializing in diabetes care products like syringes and pen needles, has positioned itself as a high-yield dividend payer since its 2022 spin-off from Becton Dickinson. Until recently, it paid a quarterly dividend of $0.15 per share, equating to an annual $0.60 and a trailing yield of about 6.5% based on recent share prices. This placed EMBC among top healthcare dividend stocks, far exceeding sector norms. However, on May 5, 2026, the board slashed the quarterly payout to $0.01 per share to redirect capital toward debt repayment and share repurchases, signaling a shift from high-yield to balanced capital allocation amid softer U.S. volumes. The revised profile suits conservative income investors less, but retains appeal for those eyeing total returns.

Dividend History and Growth

Since its inception as a public company in 2022, Embecta Corp. (EMBC) consistently paid $0.15 quarterly dividends, with ex-dates including Feb 27, 2026; Dec 5, 2025; Aug 29, 2025; and earlier back to Aug 2022. This steady $0.60 annual payout reflected a commitment to returning cash to shareholders, aligned with its targeted 20% payout of post-separation net income. No increases occurred, but reliability endured until Q2 fiscal 2026 results prompted a cut to $0.01 quarterly, announced May 5, 2026, for the June payment. The reduction follows U.S. revenue softness, prioritizing flexibility over growth or high income.

Dividend Sustainability and Payout Ratio

Historically, EMBC's dividend sustainability shone with a 25.4% payout ratio, well below 50-60% thresholds for caution, and ample earnings coverage (TTM EPS $2.36). TTM operating cash flow reached $214 million, with levered free cash flow (FCF) at $189 million, easily covering prior $33 million annual dividends (based on ~55 million shares). Debt stands high at $1.41 billion, but recent reductions ($184 million in FY2025) and plans for $150 million more in 2026 bolster stability. The cut to $0.01 (~$2 million annually) alongside a $100 million buyback program enhances FCF flexibility amid challenges, suggesting improved long-term viability despite elevated leverage (net leverage 3.0x adjusted EBITDA).

Dividend Compared to Industry Peers

EMBC's trailing 6.5% yield dwarfs medical devices peers: Becton Dickinson (BDX) at 2.9%, Medtronic (MDT) ~3.5%, Stryker (SYK) ~1.1%, Zimmer Biomet (ZBH) 1.2%. Industry averages hover at 1-2% for large-caps, with many growth names like Dexcom (DXCM) and Insulet (PODD) paying none. Post-cut forward yield drops near 0.4%, aligning closer to peers but retaining income edge historically. EMBC's profile suits yield hunters versus dividend growers like BDX.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to uncover hidden gems like high-yield names in healthcare.

Is This Stock Attractive for Dividend Investors?

Embecta Corp. (EMBC) appeals to income-oriented investors who prioritize yield over growth, given its prior 6.5% trailing payout—well above peers—and low historical payout ratio signaling coverage. Those comfortable with volatility may value the total shareholder return shift: minimal $0.01 dividends plus $100 million buybacks and debt paydown for potential capital appreciation. However, conservative dividend seekers might hesitate post the May 2026 cut, prompted by U.S. softness and acquisition costs, as forward yield nears negligible levels. Long-term holders could benefit if FCF ($189 million TTM) fuels balance sheet strength in diabetes care amid rising demand. High debt warrants monitoring, but strategic pivots like Owen Mumford buy enhance diversification. Balanced appeal lies for yield-tolerant, total-return focused portfolios versus pure dividend aristocrats.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.